A Randomized, Double-blind, Active Control,parallel Group, Titration, Multicenter Study to Evaluate the Efficacy and Safety of Fimasartan.
Phase of Trial: Phase III
Latest Information Update: 06 Apr 2017
At a glance
- Drugs Fimasartan (Primary) ; Losartan
- Indications Hypertension; Renal failure
- Focus Therapeutic Use
- Sponsors Boryung Pharmaceutical
- 10 Feb 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 19 Jan 2016 Planned number of patients changed from 500 to 468 as reported by ClinicalTrials.gov record.
- 08 Dec 2015 New trial record